



Target Heart Biotec Srl

Fields of business: recombinant biopharmaceuticals for heart failure

The company has acquired a patent exclusively licensed from the University of Turin and is engaged in a R & D program for the development in preclinical animal models of a recombinant protein for the treatment of heart failure. The products supplied are new biologic drugs for cardiovascular therapy.

Email: gtarone@thbiotec.com

Web site: www.thbiotec.com